These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278 [TBL] [Abstract][Full Text] [Related]
25. Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. Yamada O; Mahfoudhi E; Plo I; Ozaki K; Nakatake M; Akiyama M; Yamada H; Kawauchi K; Vainchenker W J Clin Oncol; 2014 Jul; 32(21):e76-9. PubMed ID: 24516035 [No Abstract] [Full Text] [Related]
26. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084 [No Abstract] [Full Text] [Related]
27. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Shahjahan M; Dunphy CH; Ewton A; Zu Y; Monzon FA; Rice L; Chang CC Am J Clin Pathol; 2008 Oct; 130(4):635-41. PubMed ID: 18794058 [TBL] [Abstract][Full Text] [Related]
28. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Mali RS; Ramdas B; Ma P; Shi J; Munugalavadla V; Sims E; Wei L; Vemula S; Nabinger SC; Goodwin CB; Chan RJ; Traina F; Visconte V; Tiu RV; Lewis TA; Stern AM; Wen Q; Crispino JD; Boswell HS; Kapur R Cancer Cell; 2011 Sep; 20(3):357-69. PubMed ID: 21907926 [TBL] [Abstract][Full Text] [Related]
29. Focus on myeloproliferative diseases and myelodysplastic syndromes. Van Etten RA; Shannon KM Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959 [No Abstract] [Full Text] [Related]
30. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment. Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855 [No Abstract] [Full Text] [Related]
31. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation. Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408 [No Abstract] [Full Text] [Related]